U.S. flag

An official website of the United States government

NM_000518.5(HBB):c.2T>G (p.Met1Arg) AND beta Thalassemia

Germline classification:
Pathogenic (4 submissions)
Last evaluated:
Jul 14, 2020
Review status:
2 stars out of maximum of 4 stars
criteria provided, multiple submitters, no conflicts
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000664667.14

Allele description [Variation Report for NM_000518.5(HBB):c.2T>G (p.Met1Arg)]

NM_000518.5(HBB):c.2T>G (p.Met1Arg)

Genes:
LOC106099062:HBB recombination region [Gene]
HBB:hemoglobin subunit beta [Gene - OMIM - HGNC]
LOC107133510:origin of replication at HBB [Gene]
Variant type:
single nucleotide variant
Cytogenetic location:
11p15.4
Genomic location:
Preferred name:
NM_000518.5(HBB):c.2T>G (p.Met1Arg)
Other names:
Init CD ATG>AGG
HGVS:
  • NC_000011.10:g.5227020A>C
  • NG_000007.3:g.70596T>G
  • NG_042296.1:g.551A>C
  • NG_046672.1:g.4955A>C
  • NG_059281.1:g.5052T>G
  • NM_000518.5:c.2T>GMANE SELECT
  • NP_000509.1:p.Met1Arg
  • LRG_1232t1:c.2T>G
  • LRG_1232:g.5052T>G
  • LRG_1232p1:p.Met1Arg
  • NC_000011.9:g.5248250A>C
  • NM_000518.4:c.2T>G
  • p.?
  • p.Met1?
Protein change:
M1R; MET1ARG
Links:
Genetic Testing Registry (GTR): GTR000500319; OMIM: 141900.0344; dbSNP: rs33941849
NCBI 1000 Genomes Browser:
rs33941849
Molecular consequence:
  • NM_000518.5:c.2T>G - initiator_codon_variant - [Sequence Ontology: SO:0001582]
  • NM_000518.5:c.2T>G - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:
beta Thalassemia (BTHAL)
Synonyms:
Cooley's anemia; Erythroblastic anemia; Mediterranean anemia
Identifiers:
MONDO: MONDO:0019402; MedGen: C0005283; Orphanet: 848

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000788668Counsyl
criteria provided, single submitter

(Counsyl Autosomal Recessive and X-Linked Classification Criteria (2018))
Pathogenic
(Oct 5, 2017)
unknownclinical testing

PubMed (10)
[See all records that cite these PMIDs]

Citation Link,

SCV001244631The ITHANET community portal, The Cyprus Institute of Neurology and Genetics
no assertion criteria provided
Pathogenic
(Nov 25, 2019)
germlinecuration

PubMed (1)
[See all records that cite this PMID]

Citation Link,

SCV001363914Women's Health and Genetics/Laboratory Corporation of America, LabCorp
criteria provided, single submitter

(LabCorp Variant Classification Summary - May 2015)
Pathogenic
(Jul 14, 2020)
germlineclinical testing

PubMed (12)
[See all records that cite these PMIDs]

Citation Link,

SCV002091622Natera, Inc.
no assertion criteria provided
Pathogenic
(Mar 17, 2017)
germlineclinical testing

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing, curation
not providedunknownunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Hereditary hemolytic anemia in Korea from 2007 to 2011: A study by the Korean Hereditary Hemolytic Anemia Working Party of the Korean Society of Hematology.

Park ES, Jung HL, Kim HJ, Park SS, Bae SH, Shin HY, Song SH, Koh KN, Lyu CJ, Lim YT, Han DK, Hah JO.

Blood Res. 2013 Sep;48(3):211-6. doi: 10.5045/br.2013.48.3.211. Epub 2013 Sep 25.

PubMed [citation]
PMID:
24086942
PMCID:
PMC3786282

Molecular analysis of beta-globin gene mutations among Thai beta-thalassemia children: results from a single center study.

Boonyawat B, Monsereenusorn C, Traivaree C.

Appl Clin Genet. 2014;7:253-8. doi: 10.2147/TACG.S73058.

PubMed [citation]
PMID:
25525381
PMCID:
PMC4266330
See all PubMed Citations (15)

Details of each submission

From Counsyl, SCV000788668.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (10)
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1unknownunknownnot providednot providednot providednot providednot providednot providednot provided

From The ITHANET community portal, The Cyprus Institute of Neurology and Genetics, SCV001244631.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedcuration PubMed (1)
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

From Women's Health and Genetics/Laboratory Corporation of America, LabCorp, SCV001363914.3

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (12)

Description

Variant summary: HBB c.2T>G (p.Met1Arg) alters the initiation codon and is predicted to result either in absence of the protein or truncation of the encoded protein due to translation initiation at a downstream codon. Arginine is not a known alternative start codon for eukaryotes in nature; thus, translation would be predicted to start at the next Met in the HBB protein (which is at amino acid 56), causing a loss of translation of the normal N-terminus of the protein. Four of four in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 251128 control chromosomes (gnomAD). c.2T>G has been reported in the literature in multiple individuals affected with Beta Thalassemia (e.g. Lam_1990, Lee_2002, Su_2003). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. This codon is in a mutational hotspot where other changes [such as: p.M1I (c.3G>A, C, and T), p.M1L, p.M1K, p.M1T and p.M1V] at the same residue have also been found in HBB patients (source: HGMD). Four ClinVar submitters (evaluation after 2014) cite the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

From Natera, Inc., SCV002091622.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testingnot provided
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Oct 26, 2024